Austria's Pharmig greets VAT cut

5 October 2008

Austria's research-based pharmaceutical industry association, Pharmig, has welcomed proposals from the coalition Social Democrat-Christian Democrat government to reduce the rate of value-added tax on drugs. The group's secretary general, Jan Oliver Huber, who noted that Pharmig had been campaigning on this issue for several years, said: "by lowering the VAT on medicines two important goals are achieved." First there is a saving per year of 60.0 million euros ($86.6 million) to patients. Second, the measure will reduce some of the pressure on health insurance firms, some of which will also save the same amount.

Whether the proposals will actually be implemented must now be in some doubt, given the election results of September 28 in Austria, which has seen far-right political parties make substantial gains in Parliament. According to media reports, the election was called because of splits within the governing coalition.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight